Real-life experience with immunotherapy for liver cancer treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to gather and analyze real-world data from patients with hepatocellular carcinoma (HCC) who are treated with new immunotherapy combinations, such as atezolizumab-bevacizumab and durvalumab-tremelimumab. The goal is to evaluate the effectiveness and safety of these treatments and identify the best sequences for managing advanced liver cancer. Additionally, the study seeks to discover clinical and laboratory markers that can predict treatment responses, thereby personalizing care and optimizing patient outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Hepatocellular carcinoma not amenable to locoregional procedures
* Candidate to frontline systemic treatment with atezolizumab-bevacizumab or other immunotherapies

Exclusion Criteria:

* Concurrent treatment with other antineoplastic agents
* Other active neoplasia

Where it's running

• Ospedali Riuniti Ancona, Via Conca, 71, 60126 Torrette AN
  Torrette, An, Italy Recruiting
• AUSL Bologna Via Castiglione 15 40136 Bologna BO
  Bologna, Bo, Italy Recruiting
• IRCCS Azienda Ospedaliero-Universitaria di Bologna (Oncology Unit), Bologna, BO 40136
  Bologna, Bo, Italy Recruiting
• IRCCS Azienda Ospedaliero-Universitaria di Bologna (Semiotics Unit)
  Bologna, Bo, Italy Recruiting
• IRCCS Azienda Ospedaliero-Universitaria di Bologna
  Bologna, Bo, Italy Recruiting
• Ospedali Riuniti. Viale Pinto Luigi, 1, 71122 Foggia FG.
  Foggia, Fg, Italy Recruiting

Study contacts

• Principal investigator: Francesco Tovoli, MD — IRCCS Azienda Ospedaliero-Universitaria di Bologna
• Study coordinator: Francesco Tovoli, MD
• Email: francesco.tovoli@unibo.it
• Phone: +390512142214

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Blood biomarkers to predict response to atezolizumab plus bevacizumab in hepatocellular carcinoma

  This study tests whether blood-based biomarkers can predict which patients with advanced liver cancer will respond to first-line atezolizumab plus bevacizumab.

  Recruiting Shanghai Zhongshan Hospital · Shanghai, Shanghai Municipality · NCT07734857

• TIPS benefits for people with hepatocellular carcinoma taking Tecentriq (atezolizumab) plus Avastin (bevacizumab) as first-line therapy.

  This study will try to see if placing a TIPS device helps people with advanced or unresectable hepatocellular carcinoma who are starting first-line treatment with Tecentriq plus Avastin.

  Recruiting Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · Düsseldorf, North Rhine-Westphalia · NCT07365930

• FOLFOX chemotherapy with atezolizumab and bevacizumab after progression on atezolizumab plus bevacizumab for advanced liver cancer

  This trial will test whether giving FOLFOX chemotherapy together with continued atezolizumab and bevacizumab helps people with advanced hepatocellular carcinoma whose cancer progressed on prior atezolizumab plus bevacizumab.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT07192185

• Preventing esophageal varices in liver cancer patients treated with specific medications

  This study is testing whether treating liver cancer patients with specific medications can help prevent the worsening of esophageal varices and reduce the risk of bleeding.

  Recruiting Tanta University · Tanta, Gharbyea · NCT06961526

• Combining radiotherapy and immunotherapy for advanced liver cancer before transplant

  This study is testing if combining radiation therapy with immunotherapy can help people with advanced liver cancer get better and qualify for a liver transplant.

  Recruiting Phase 1/2 University Health Network, Toronto · London, Ontario and 1 other locations · NCT06725121

• Evaluating RZ-001 with Valganciclovir and Atezolizumab/Bevacizumab for Liver Cancer

  This study is testing a new combination treatment for advanced liver cancer to see if it is safe and effective for patients with a specific type of the disease.

  Recruiting at 9 sites Phase 1/2 Rznomics, Inc. · Busan and 8 other locations · NCT06695026

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.